27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Voyager Therapeutics Inc (NASDAQ:VYGR) faded this week on news of a CEO transition, but the firm caught a boost Friday from a new advocate.
The Rating
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Morgan Stanley analyst Matthew Harrison initiated coverage of Voyager with an Overweight rating and $36 price target.
The Thesis
The neuroscience biotech’s lead candidate, a gene therapy for Parkinson’s disease, demonstrated a durable, exposure-dependent response in Phase 1 studies that inspire confidence in a $1-billion-plus market potential, Harrison said in a Friday note.
The treatment has the opportunity to poach market share from deep brain stimulation, which sees about $250 million in U.S. sales, the analyst said.
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
Morgan Stanley is projecting Phase 2 and 3 success based on positive early stage data and the ability of Voyager’s MRI-guided delivery to improve target precision. The two trials will run concurrently and provide “a clear back-up strategy limiting risk," Harrison said.
“While we remain positive, the key risk in Phase 3 is that the initial effect size is not reproducible ... making the therapy not commercially relevant,” the analyst said.
Voyager has near-term catalysts in durability updates and advancements in assets treating amyotrophic lateral sclerosis, Friedreich’s Ataxia and Huntington’s disease, according to Morgan Stanley.
Price Action
Voyager shares were down 1.68 percent at $18.99 at the time of publication Friday morning.
Related Links:
4 Biotechs Boosted By Spark Therapeutic's FDA News
Analyst: Denali Therapeutics' Neuroscience Work Could Lead To Near-Term Upside
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.